[ILMN] Illumina: Q3 2026 Earnings Test Clinical Sequencing Growth and Margins

Illumina is a leading global supplier of sequencing and array-based genetic analysis platforms, selling sequencers, reagent consumables and related services to genomic research centers, academic institutions, hospitals, pharmaceutical companies and commercial molecular diagnostics labs[1]. According to the Drillr earnings calendar, Illumina Q3 2026 earnings will be discussed on a call on 2026-10-29 at 1:30 pm Pacific Time, covering the third quarter of fiscal 2026[2]. In the latest disclosed period, the second quarter ended June 28, 2026, revenue was $1.159 billion, up 9.5% year over year and up 8.1% on a rest-of-world (ROW) organic basis that excludes currency, acquisitions and Greater China; GAAP operating margin was 21.1%, non-GAAP operating margin was 22.5%, GAAP diluted EPS was $1.35, non-GAAP diluted EPS was $1.31, and free cash flow for the quarter was $162 million[3]. On July 30, management guided third-quarter revenue to $1.14 billion to $1.16 billion, non-GAAP EPS to $1.33 to $1.38, non-GAAP operating margin to about 24% and ROW organic growth to about 4.5%[4]. It also raised full-year revenue guidance to $4.60 billion to $4.64 billion and non-GAAP EPS guidance to $5.30 to $5.40, while holding full-year non-GAAP operating margin guidance at 23.4% to 23.6%[3]. Analyst estimates compiled by Drillr on 2026-10-23 put third-quarter revenue at $1.153 billion (10 analysts) and EPS at $1.36 (12 analysts), both inside the company's guided ranges[5].

Three things matter most in this report. The first is whether clinical consumables growth holds: clinical sequencing consumables grew about 15% ROW organic in the second quarter, down from roughly 20% in the first quarter, while the US and Canada still grew more than 20%[4][6]. The third quarter will show whether that slowdown reflects regional disruption in the Middle East and Latin America, or NovaSeq X price reductions starting to absorb volume growth. The second is whether NovaSeq X placements continue: more than 95 units were placed in the second quarter and sequencing instrument revenue rose about 30%[4][7], yet full-year instrument guidance calls only for low single-digit growth, and a sharp second-half drop in placements would thin the consumables base for 2027. The third is whether margins reach the roughly 24% guide: non-GAAP gross margin fell to 68.2% in the second quarter from 69.4% a year earlier[3], which the company attributed to a higher instrument mix, rising memory and freight costs and lower-margin SomaLogic revenue[7], so third-quarter gross margin will show whether those pressures have peaked.

Company Background and Business Structure

Illumina is a platform company that sells sequencers and then earns recurring consumables revenue from its installed base. The company is incorporated in Delaware and headquartered in San Diego, California, and its customers include genomic research centers, academic institutions, government laboratories, hospitals, and pharmaceutical and biotechnology companies[1]. It completed the spin-off of GRAIL in June 2024, and that separation drove the year-over-year improvement in gross margin in 2025[1]. In June 2025 it agreed with Standard BioTools to acquire the proteomics company SomaLogic for $350 million in cash, plus royalty streams and up to $75 million in milestone payments, to advance its multiomics strategy[1].

Illumina reports a single segment and discloses revenue by product type, with consumables making up the bulk. In 2025, consumables revenue was $3.227 billion, up 2% and roughly 74% of total revenue; instrument revenue was $482 million, down 4%; and service and other revenue was $634 million, also down 4%[1]. Consumables include reagents, flow cells and library preparation kits that customers use up each time they run an instrument, so clinical labs buy them continuously in line with test volume; instruments are recognized when shipped and installed and build the installed base for later consumables sales[1]. In the second quarter of 2026, sequencing consumables revenue was $775 million, sequencing instruments $125 million, sequencing service and other $154 million, and microarrays and other $105 million, the last including SomaLogic's contribution[4].

Revenue is concentrated in North America and has been visibly affected by restrictions in Greater China. In the second quarter of 2026, the US and Canada contributed $653 million, Europe, the Middle East, Africa and Latin America $368 million, Asia-Pacific $82 million and Greater China $56 million[7]. Illumina was placed on China's Unreliable Entities List in early 2025, and Greater China revenue for 2025 was $243 million, down $65 million from the prior year[1]; exports of sequencers to Chinese customers have since been permitted again, but only with case-by-case approval[1].

Financial History and Current Position

The annual record shows flat revenue over three years but a swing back to profit in 2025. Total revenue fell from $4.504 billion in 2023 to $4.372 billion in 2024 and was $4.343 billion in 2025[1]. Operating results were losses of $1.069 billion in 2023 and $833 million in 2024, driven mainly by goodwill and intangible impairments; in 2025 the company earned operating profit of $807 million and net income of $850 million, with GAAP gross margin of 66.1%[1]. Operating cash flow was $1.079 billion in 2025, up from $837 million in 2024, and backlog stood at $738 million at year-end[1].

The first two quarters of 2026 show revenue re-accelerating while margins remain below the prior year. First-quarter revenue was $1.091 billion, up 4.8% with ROW organic growth of 3.5%, non-GAAP operating margin was 21.9%, and GAAP and non-GAAP diluted EPS were $0.87 and $1.15[8]. Second-quarter revenue was $1.159 billion, up 9.5%, with non-GAAP gross margin of 68.2% and operating margin of 22.5%, compared with 69.4% and 23.8% a year earlier[3]. Second-quarter operating cash flow was $201 million, below $234 million a year earlier; capital expenditures were $39 million and free cash flow was $162 million, while first-half free cash flow of $412 million matched the prior-year period[3].

The balance sheet went through a round of cash use and refinancing in 2026. The company spent $366 million on share repurchases in the first half, and on June 28 it still had $279 million and $1.5 billion of authorization left under its 2024 and 2026 programs[7]; cash, cash equivalents and short-term investments were $1.17 billion on the same date[3]. In August Illumina issued $300 million of 4.950% notes due 2029 and used the proceeds, together with cash on hand, to repay the $500 million of 4.650% notes due September 9, 2026[9]; the same month it signed a $1.0 billion five-year unsecured revolving credit facility[10], and in October it set up a commercial paper program capped at $1.0 billion outstanding[11].

Operating Model

On the revenue side, the core equation is installed base times usage per instrument times price per unit of data. Consumables revenue roughly equals installed base × usage per instrument × price per unit of data, with clinical customers buying continuously according to test volume and research customers buying by project and funding[1]; instrument revenue roughly equals units placed × unit price and is recognized in the quarter of shipment and installation[1]. Management said new NovaSeq X instruments typically take 6-9 months to reach normalized utilization, so most of the consumables benefit from recent strong placements will show up in 2027[4]. Placements today are therefore a leading indicator, and consumables growth trails them by two to three quarters.

On the profit side, product mix and input costs are the main variables. Consumables carry higher gross margins than instruments and SomaLogic services, so a rising instrument share directly lowers gross margin; the 10-Q attributes the second-quarter change in GAAP gross margin to higher tariff costs, a greater instrument mix, rising memory and freight costs and newly consolidated SomaLogic revenue[7]. On tariffs, the largest cost impact comes from importing products from the Singapore manufacturing facility into the United States[1]. Consumables were 73.5% of second-quarter revenue, down from 76.6% a year earlier[7], and management tied its guide for about 150 basis points of sequential operating-margin expansion in the third quarter to a higher consumables mix and efficiency gains[4].

On the cash side, the model relies on strong profit conversion and light capital spending. Operating cash flow roughly equals net income plus stock compensation and depreciation and amortization, less working-capital changes, and was $1.079 billion in 2025[1]; second-quarter capital expenditures were $39 million and depreciation and amortization was $70 million[3]. Free cash flow goes mainly to buybacks and acquisitions, with $366 million repurchased in the first half of 2026[7], and after the September note maturity liquidity relies more on new notes, the revolver and commercial paper[9][10][11].

Industry and Competitive Position

Illumina's advantage rests on its large installed base and deep clinical customer relationships, but its 10-K explicitly warns that competition will intensify. The company says its family of sequencing platforms sets the industry standard, and it faces competition from suppliers of other sequencing platforms, arrays, proteomics and molecular diagnostics technologies[1]. The 10-K also notes that a growing share of revenue comes from a small number of large centralized labs, and that customer concentration may bring greater pricing pressure and weaker negotiating leverage[1]. The available materials do not give competitors' share or revenue on a comparable basis, so this section cannot quantify the competitive gap.

End markets are split between strong clinical demand and weak research demand. Clinical made up about 65% of sequencing consumables revenue in the second quarter and grew 15% ROW organic, while research and applied markets declined 7%[4]; management said research and academic customers remain cautious because of funding uncertainty[6]. By the end of the second quarter, 83% of total sequencing volumes and 78% of clinical volumes had moved to the NovaSeq X platform[4], which deepens customer reliance on the new platform but also means most of the price step-down from migration has already happened.

Core Debates

Clinical testing volumes are still growing fast, yet clinical consumables growth slowed from about 20% to 15%. Is that a regional disruption, or is NovaSeq X pricing starting to absorb volume growth?

This debate determines whether the raised full-year guidance holds up. Consumables were about 74% of total revenue in 2025[1], and clinical is about 65% of sequencing consumables[4]. The company raised full-year ROW organic revenue growth guidance from 2% to 4% to above 5%[3], mainly on the basis of mid-teens clinical consumables growth, while still planning for mid-to-high single-digit declines in research and applied consumables[4].

The current evidence shows clinical still growing, but more slowly. Clinical consumables grew about 20% in the first quarter[6] and about 15% in the second, with the US and Canada still above 20% and research and applied down 7%[4]. Second-quarter sequencing consumables revenue was $775 million, up 4.7%, after $726 million and 4.3% growth in the first quarter[7][12]. Management attributed the sequential slowdown in clinical growth to short-term disruptions in the Middle East and Latin America and raised its full-year clinical growth guidance to mid-teens[4].

An alternative reading is equally consistent with the data. NovaSeq X has a lower cost per gigabase, so migration dilutes price and makes revenue grow more slowly than data volume; customers may also have bought extra consumables while running old and new platforms in parallel, and once migration is complete, volume elasticity may not fully offset the lower price. Because total sequencing consumables growth is roughly a weighted blend of clinical growth and the research decline at about 65% and 35%, each few points of clinical slowdown directly drag down total consumables growth.

In the third quarter, three numbers matter: whether clinical consumables growth stays above 12% with the US and Canada still above 20%, whether sequencing consumables revenue keeps growing about 4% to 5% year over year, and whether the research and applied decline stays within the mid-to-high single-digit range. If sequencing consumables growth stays above 4% and clinical growth is at least 13%, the regional-disruption explanation gains support; if clinical growth drops to single digits for reasons other than regional disruption, the durability of clinical growth has been overstated.

More than three years after launch, NovaSeq X still placed over 95 units in a quarter. Is that sustained clinical capacity expansion, or a one-time capacity build?

This debate bears on the consumables base for 2027. Instruments were only about 11% of total revenue in 2025[1], but new placements determine later consumables usage; the company said most of the consumables revenue from those placements will appear in 2027 and reaffirmed its target of high single-digit full-year revenue growth in 2027[4].

Placement and order data for the first half were strong. Second-quarter sequencing instrument revenue was $125 million, up about 30%[7], with more than 95 NovaSeq X units placed alongside 10 NovaSeq 6000 units[4]; first-quarter placements exceeded 80 units, about 20 more than a year earlier[6]. On June 28, remaining performance obligations on instrument, consumables and service contracts were about $1.0 billion, roughly 83% of which is expected to convert to revenue within 12 months[7], compared with backlog of $738 million at the end of 2025[1].

The company's own full-year guidance nonetheless implies a year-over-year instrument decline in the second half. Management still guides full-year sequencing instruments to low single-digit ROW organic growth, with elevated placements continuing in the second half but year-over-year growth moderating[4]. An alternative reading is that large clinical customers concentrated capacity builds for new tests in the first half, placements fall back in the second half, and utilization ramps on new instruments could take longer than 6-9 months; placements also raise the instrument share of revenue, which weighs on gross margin in the quarter.

In the third quarter, the markers are whether NovaSeq X placements are at least 80 units, whether sequencing instrument revenue lands between $100 million and $125 million, and whether remaining performance obligations hold at about $1.0 billion. Placements of 80 or more with no decline in remaining performance obligations would support sustained clinical expansion; fewer than 70 placements with remaining performance obligations below $900 million would indicate that the first half pulled demand forward.

Instrument mix, memory and freight costs held down second-quarter margins. Can the guided operating margin of about 24% for the third quarter be delivered?

This debate decides how credible the full-year EPS guidance is. The company kept full-year non-GAAP operating margin guidance at 23.4% to 23.6% while raising EPS guidance to $5.30 to $5.40[3], yet non-GAAP operating margins in the first two quarters were only 21.9% and 22.5%[8][3], so the full-year target depends on a clear second-half improvement.

Second-quarter margin pressure has identifiable sources. Non-GAAP gross margin was 68.2%, below 69.4% a year earlier, and operating margin was 22.5%, below 23.8%[3]. The 10-Q attributes the gross margin change to a higher instrument mix, rising memory costs, freight costs pushed up by conflict in the Middle East and lower-margin SomaLogic revenue[7]. Management said the bulk of the higher memory costs is already reflected in second-quarter gross margin, the company has secured inventory for the next several quarters, and its instruments do not use GPU architecture[4].

An alternative reading is that the improvement may be delayed. Memory and freight costs may still be rising, and the instrument share may stay elevated while clinical customers migrate, pushing margin recovery into 2027. On mix, consumables were 73.5% of second-quarter revenue versus 76.6% a year earlier[7], and management's guide for about 150 basis points of sequential expansion rests on that consumables share recovering[4].

In the third quarter, the markers are whether non-GAAP operating margin reaches about 24%, whether non-GAAP gross margin exceeds 68.2%, and whether the consumables share of revenue rises. An operating margin of 24% or higher would support the view that mix improvement lifts margins; gross margin below 67.5% with the company citing cost increases would indicate that cost pressure has not peaked.

Risks and Falsifiers

Chinese regulation remains a risk that could widen abruptly. Since Illumina was placed on the Unreliable Entities List, sequencer exports require case-by-case approval, fines or restrictions on sales, imports and exports could expand, and a forced retreat from China could lead to material impairment charges[1]. The exposure sits in Greater China revenue: $243 million in 2025, down $65 million from the prior year[1], and $56 million in the second quarter of 2026 (versus $63 million a year earlier) and $108 million in the first half (versus $135 million)[7]. If the year-over-year decline in Greater China revenue narrows in the third quarter with no new regulatory penalties or restrictions, the current concern would ease.

Liquidity risk comes from buybacks, acquisitions and debt maturities drawing on cash at the same time. Cash and short-term investments were $1.17 billion on June 28[3], first-half buybacks were $366 million[7], and the $500 million of notes due in September was repaid with $300 million of new notes plus cash on hand[9], leaving the company more reliant on its $1.0 billion revolver and a commercial paper program capped at $1.0 billion[10][11]. The exposed financial lines are the cash balance and interest cost. If third-quarter free cash flow stays above $150 million, cash and short-term investments remain at or above roughly $900 million after the repayment, and no commercial paper is drawn, this concern would be falsified.

Funding pressure in research markets could prove deeper than guided. Research and applied is about 35% of sequencing consumables and declined 7% in the second quarter[4], and management said research and academic customers remain cautious because of funding uncertainty[6]. On roughly $270 million of second-quarter research consumables revenue, each additional 5 percentage points of decline would reduce quarterly revenue by about $13 million to $14 million. If the research and applied consumables decline narrows to within 5% in the third quarter, this risk would be falsified.

The buying cycles of large clinical customers can amplify quarterly swings in instrument revenue. The 10-K warns that revenue is increasingly concentrated in a few large centralized labs and that customer concentration brings pricing pressure and weaker negotiating leverage[1]; first-half sequencing instrument revenue was $243 million[7], and if the second half falls below the prior-year period, the full year would grow only in the low single digits[4]. If placements are at least 80 units in both the third and fourth quarters with no disclosed delay in large-customer orders, this risk would be falsified.

Input costs could keep weighing on gross margin. Higher memory chip prices, freight increases tied to conflict in the Middle East[7] and tariffs on products imported from Singapore into the United States[1] all flow directly into product costs. On second-quarter revenue of $1.159 billion, each percentage point of non-GAAP gross margin is worth about $12 million of quarterly gross profit[3]. If third-quarter non-GAAP gross margin returns to 68.5% or higher, this risk would be falsified.

What to Watch Next

• Clinical consumables: clinical growth was about 15% in the second quarter (US and Canada above 20%) and sequencing consumables revenue was $775 million, up 4.7%. Clinical growth of at least 13% with consumables growth above 4% supports the regional-disruption reading; a drop to single digits weakens the case for durable clinical growth.
• NovaSeq X placement cycle: more than 95 units, $125 million of instrument revenue and about $1.0 billion of remaining performance obligations in the second quarter. At least 80 units with stable obligations supports sustained expansion; fewer than 70 units and obligations below $900 million signal pulled-forward demand.
• Margin recovery: non-GAAP operating margin of 22.5%, gross margin of 68.2% and a consumables share of 73.5% in the second quarter. An operating margin of 24% or higher supports mix-driven improvement; gross margin below 67.5% means cost pressure has not peaked.
• Liquidity: second-quarter free cash flow of $162 million and $1.17 billion of cash and short-term investments. Free cash flow above $150 million, cash at or above about $900 million after the September repayment and no commercial paper drawn would ease the concern.

Conclusion

Illumina's business is driven jointly by consumables sales tied to clinical test volume and by NovaSeq X placements, and in the first half of 2026 revenue re-accelerated while margins have not yet caught up. Second-quarter revenue was $1.159 billion, up 9.5%, and non-GAAP operating margin was 22.5%, below 23.8% a year earlier[3]; clinical consumables grew about 15% while research and applied declined 7%[4]. The central unresolved relationship is whether clinical volume growth can still translate into consumables revenue growth after the price dilution from NovaSeq X migration, and whether a recovering consumables share can push operating margin back to about 24%.

After the 2026-07-30 results release, searches of Drillr news and research found no independent outside assessment of Illumina, and the web turned up only call recaps and aggregator content without verifiable authors or dates, so this article cites no external views and does not treat any market opinion as a shared view. For now, readers can rely only on the company's own disclosures, management's guidance and the quarterly figures compiled from analysts.

Over the next few quarters, the current understanding of durable growth and margin repair would strengthen materially if clinical consumables growth settles in the mid-teens, NovaSeq X placements stay at 80 or more per quarter with no decline in remaining performance obligations, non-GAAP gross margin returns to 68.5% or higher and operating margin reaches about 24%. Conversely, it would weaken if clinical growth falls to single digits, placements drop below 70, gross margin slips below 67.5%, or cash after the debt repayment falls clearly below about $900 million and the company begins drawing on commercial paper.

Sources

[1] ILMN FY2025 10-K filed 2026-02-12 · 2026-02-12 · 10-K · https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm

[2] ILMN earnings calendar updated 2026-10-24 · 2026-10-24 · Drillr earnings calendar

[3] ILMN Q2 2026 8-K filed 2026-07-30 · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/1110803/000111080326000155/q226earningsrelease.htm

[4] ILMN Q2 2026 earnings call 2026-07-30 · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[5] Drillr analyst estimates ILMN Q3 2026 retrieved 2026-10-23 · 2026-10-23 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[6] ILMN Q1 2026 earnings call 2026-04-30 · 2026-04-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[7] ILMN Q2 2026 10-Q filed 2026-07-31 · 2026-07-31 · 10-Q · https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/ilmn-20260628.htm

[8] ILMN Q1 2026 8-K filed 2026-04-30 · 2026-04-30 · 8-K · https://www.sec.gov/Archives/edgar/data/1110803/000111080326000087/q126earningsrelease.htm

[9] ILMN 8-K filed 2026-08-17 (4.950% notes due 2029) · 2026-08-17 · 8-K · https://www.sec.gov/Archives/edgar/data/1110803/000119312526354010/d51146d8k.htm

[10] ILMN 8-K filed 2026-08-13 (revolving credit facility) · 2026-08-13 · 8-K · https://www.sec.gov/Archives/edgar/data/1110803/000095015726000888/form8-k.htm

[11] ILMN 8-K filed 2026-10-13 (commercial paper program) · 2026-10-13 · 8-K · https://www.sec.gov/Archives/edgar/data/1110803/000111080326000195/ilmn-20261013.htm

[12] ILMN Q1 2026 10-Q filed 2026-05-04 · 2026-05-04 · 10-Q · https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm